Loading…
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $4.1B | $1.0B | $375M | $434M | 4.6% | 5.1% | -4.4% |
| 2024 | $3.9B | $1.1B | $392M | $288M | 4.9% | 8.4% | 33.3% |
| 2023 | $3.6B | $886M | $294M | $215M | 3.9% | 8.6% | -23.7% |
| 2022 | $3.3B | $879M | $386M | $450M | 5.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 3,308.40 | 3,593.20 | 3,895.40 | 4,092.40 |
| Cost Of Revenue | - | 1,168.80 | 1,235.30 | 1,299.70 | 1,410.30 |
| Gross Profit | - | 2,139.60 | 2,357.90 | 2,595.70 | 2,682.10 |
| Operating Expense | - | 1,632 | 1,824.80 | 1,890 | 1,999.20 |
| Operating Income | - | 507.60 | 533.10 | 705.70 | 682.90 |
| EBITDA | - | 878.70 | 885.90 | 1,071.70 | 1,043.90 |
| EBIT | - | 532.60 | 518.20 | 696.60 | 666.50 |
| Pretax Income | - | 475.30 | 412.90 | 582.30 | 566.50 |
| Tax Provision | - | 89.50 | 118.70 | 190 | 191.60 |
| Net Income | - | 385.80 | 294.20 | 392.30 | 374.90 |
| Net Income Common Stockholders | - | 385.80 | 294.20 | 392.30 | 374.90 |
| Total Expenses | - | 2,800.80 | 3,060.10 | 3,189.70 | 3,409.50 |
| Interest Expense | - | 57.30 | 105.30 | 114.30 | 100 |
| Research And Development | - | 110.30 | 137.40 | 155.10 | 172.20 |
| Selling General And Administration | - | 1,342.20 | 1,501.20 | 1,533.70 | 1,627.80 |
| Normalized EBITDA | - | 878.70 | 885.90 | 1,076.90 | 1,051.90 |
| Normalized Income | - | 385.80 | 294.20 | 395.80 | 380.20 |
| Market Cap | 12,569.27 | 12,569.27 | 12,569.27 | 12,569.27 | 12,569.27 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| The Cooper Companies, Inc.this co. | COO | $12.6B | 33.53↑ premium | 1.53 | 4.6% | 14.33 |
| STERIS plc | STE | $21.8B | 35.42 | 3.30 | 9.3% | 17.52 |
| Incyte Corporation | INCY | $18.5B | 14.64 | 3.65 | 24.9% | 8.96 |
| Waters Corporation | WAT | $18.4B | 47.33 | 11.88 | 25.1% | 30.39 |
| Zimmer Biomet Holdings, Inc. | ZBH | $18.1B |
| - |
| - |
| - |
| - |
| - |
| - |
| 25.05 |
| 1.39 |
| 5.6% |
| 11.09 |
| Align Technology, Inc. | ALGN | $13.7B | 33.09 | 3.35 | 10.1% | 15.31 |
| Solventum Corporation | SOLV | $11.9B | 7.64 | 2.35 | 30.8% | 6.29 |
| DaVita Inc. | DVA | $11.3B | 13.41 | -15.38 | -114.7% | 8.41 |
| Universal Health Services, Inc. | UHS | $11.1B | 7.15 | 1.46 | 20.5% | 5.71 |
| Peer Median | - | 19.85 | 2.83 | 15.3% | 10.03 | |